RT Journal Article
SR Electronic
T1 The Evolving Landscape of Substance Use Disorder Mortality in the United States: A Spatiotemporal Analysis of Emerging Hotspots and Vulnerable Populations (2005-2020)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.08.24310099
DO 10.1101/2024.07.08.24310099
A1 Escobar, Santiago
A1 MacKinon, Neil J.
A1 Ambade, Preshit
A1 Hoffman, Zach
A1 Cuadros, Diego F
YR 2024
UL http://medrxiv.org/content/early/2024/07/09/2024.07.08.24310099.abstract
AB The escalating Substance Use Disorder (SUD) crisis in the U.S., marked by a significant rise in mortality since 1999, underscores the urgent need for a comprehensive analysis of its spatiotemporal dynamics. This study aims to elucidate the heterogeneous geospatial distribution of SUD mortality, identifying specific locations where vulnerable communities face heightened risk. By examining SUD mortality data from the CDC for the period 2005-2020, we applied scan statistics to delineate temporal and geospatial clusters of elevated SUD-related deaths, further dissecting these patterns across racial subpopulations and regions. Our findings reveal 27 distinct clusters nation-wide, predominantly emerging post-2013 and persisting until 2020, indicating a shifting epicenter of the epidemic. Notably, the white subpopulation was associated with 26 clusters, closely mirroring the broader national trends, yet with a pronounced concentration in the eastern U.S. Conversely, the black subpopulation demonstrated a different pattern, with 17 clusters arising between 2013 and 2020, primarily post-2015, suggesting a temporal and spatial divergence in the impact of the epidemic across racial subpopulations. This analysis not only highlights the critical need for targeted public health interventions and policies but also calls for continued surveillance to monitor and mitigate the evolving SUD crisis. By understanding the complex spatiotemporal and racial variations in SUD mortality, we can better allocate resources, develop effective prevention strategies, and support the communities most in need.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://www.cdc.gov/nchs/nvss/nvss-restricted-data.htm https://www.cdc.gov/nchs/nvss/nvss-restricted-data.htm